Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free THMO Stock Alerts

ThermoGenesis (THMO) Competitors

ThermoGenesis logo
Compare

THMO vs. HTGMQ, BTTX, AFIB, CMRA, and STAB

Should you buy ThermoGenesis stock or one of its competitors? ThermoGenesis's main competitors and comparable companies include HTG Molecular Diagnostics (HTGMQ), Better Therapeutics (BTTX), Acutus Medical (AFIB), Comera Life Sciences (CMRA), and Statera Biopharma (STAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ThermoGenesis compare to HTG Molecular Diagnostics?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and ThermoGenesis (NASDAQ:THMO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

ThermoGenesis has higher revenue and earnings than HTG Molecular Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

HTG Molecular Diagnostics has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
ThermoGenesis N/A N/A N/A

In the previous week, HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
ThermoGenesis Neutral

5.8% of ThermoGenesis shares are held by institutional investors. 2.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 78.0% of ThermoGenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ThermoGenesis beats HTG Molecular Diagnostics on 5 of the 7 factors compared between the two stocks.

How does ThermoGenesis compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and ThermoGenesis (NASDAQ:THMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

ThermoGenesis has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
ThermoGenesis N/A N/A N/A

In the previous week, Better Therapeutics had 1 more articles in the media than ThermoGenesis. MarketBeat recorded 1 mentions for Better Therapeutics and 0 mentions for ThermoGenesis. Better Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
ThermoGenesis Neutral

Summary

ThermoGenesis beats Better Therapeutics on 5 of the 8 factors compared between the two stocks.

How does ThermoGenesis compare to Acutus Medical?

ThermoGenesis (NASDAQ:THMO) and Acutus Medical (NASDAQ:AFIB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

ThermoGenesis has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ThermoGenesis' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Acutus Medical -272.74%-311.64%-11.57%

5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by company insiders. Comparatively, 5.2% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Acutus Medical Neutral

ThermoGenesis has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

ThermoGenesis has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.7, meaning that its share price is 470% more volatile than the broader market.

Summary

ThermoGenesis beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

How does ThermoGenesis compare to Comera Life Sciences?

ThermoGenesis (NASDAQ:THMO) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Comera Life Sciences Neutral

ThermoGenesis has higher revenue and earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

5.8% of ThermoGenesis shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ThermoGenesis has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Summary

ThermoGenesis beats Comera Life Sciences on 6 of the 7 factors compared between the two stocks.

How does ThermoGenesis compare to Statera Biopharma?

ThermoGenesis (NASDAQ:THMO) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Statera Biopharma N/A N/A N/A

5.8% of ThermoGenesis shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ThermoGenesis has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Statera Biopharma has lower revenue, but higher earnings than ThermoGenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Statera BiopharmaN/AN/AN/AN/AN/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Statera Biopharma Neutral

Summary

ThermoGenesis beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

Get ThermoGenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for THMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

THMO vs. The Competition

Export
MetricThermoGenesisLaboratory apparatus & furniture IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$1K$7.02B$13.06B
Dividend YieldN/AN/A2.57%10.45%
P/E Ratio0.00N/A271.2725.33
Price / SalesN/A0.00583.7676.83
Price / CashN/AN/A70.4850.90
Price / BookN/AN/A12.926.25
Net Income-$17.98M-$17.98M$3.45B$347.82M

ThermoGenesis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
AFIB
Acutus Medical
N/A$0.00
flat		N/A-80.0%$3K$7.16MN/A340
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:THMO) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel